1
|
Wang W, Chen YL, Gou PP, Wu PL, Shan KS, Zhang DL. Focal lymphoblastic transformation of chronic myelogenous leukemia develops into erythroid leukemia: A case report. World J Clin Cases 2023; 11:5780-5788. [PMID: 37727723 PMCID: PMC10505995 DOI: 10.12998/wjcc.v11.i24.5780] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/19/2023] [Revised: 07/03/2023] [Accepted: 07/24/2023] [Indexed: 08/24/2023] Open
Abstract
BACKGROUND We present a case of focal lymphoblastic transformation to erythroid leukemia following acute myeloblastic transformation in a patient with chronic myelogenous leukemia (CML) and discuss its mechanism of occurrence and development. CASE SUMMARY The presence of the Philadelphia (Ph) chromosome was identified through karyotype analysis, while the BCR-ABL fusion gene was detected using quantitative real-time polymerase chain reaction of the peripheral blood sample. Fluorescence in situ hybridization was used to detect the expression of the BCR-ABL gene in the lymphoma. Antigen expression and gene mutations in the primitive cells were detected by flow cytometry. The analysis confirmed the presence of CML along with focal lymphoblastic transformation to erythroid leukemia. Additionally, the patient was found to have secondary erythroid leukemia, along with multiple new gene mutations and abnormalities in complex karyotypes of chromosomes. CONCLUSION Our findings suggest a possible molecular basis for the focal lymphoblastic transformation secondary to myeloblastic transformation in patients with CML.
Collapse
Affiliation(s)
- Wei Wang
- Department of Hematology, The 909th Hospital of PLA (Southeast Hospital Affiliated to Xiamen University), Zhangzhou 363000, Fujian Province, China
| | - Ya-Ling Chen
- Department of Hematology, The 909th Hospital of PLA (Southeast Hospital Affiliated to Xiamen University), Zhangzhou 363000, Fujian Province, China
| | - Pan-Pan Gou
- Department of Hematology, The 909th Hospital of PLA (Southeast Hospital Affiliated to Xiamen University), Zhangzhou 363000, Fujian Province, China
| | - Pei-Lin Wu
- Department of Hematology, The 175th Hospital of PLA (Southeast Hospital Affiliated to Xiamen University), Zhangzhou 363000, Fujian Province, China
| | - Kun-Sheng Shan
- Department of Hematology, The 909th Hospital of PLA (Southeast Hospital Affiliated to Xiamen University), Zhangzhou 363000, Fujian Province, China
| | - Dong-Liang Zhang
- Department of Hematology, The 909th Hospital of PLA (Southeast Hospital Affiliated to Xiamen University), Zhangzhou 363000, Fujian Province, China
| |
Collapse
|
2
|
Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies. Curr Hematol Malig Rep 2022; 17:181-197. [PMID: 36258106 DOI: 10.1007/s11899-022-00679-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/14/2022] [Indexed: 01/27/2023]
Abstract
PURPOSE OF REVIEW Despite the adoption of tyrosine kinases inhibitors (TKIs) as molecular targeted therapy in chronic myeloid leukemia, some patients do not respond to treatment and even experience disease progression. This review aims to give a broad summary of advances in understanding of the mechanisms of therapy resistance, as well as management strategies that may overcome or prevent the emergence of drug resistance. Ultimately, the goal of therapy is the cure of CML, which will also require an increased understanding of the leukemia stem cell (LSC). RECENT FINDINGS Resistance to tyrosine kinase inhibitors stems from a range of possible causes. Mutations of the BCR-ABL1 fusion oncoprotein have been well-studied. Other causes range from cell-intrinsic factors, such as the inherent resistance of primitive stem cells to drug treatment, to mechanisms extrinsic to the leukemic compartment that help CML cells evade apoptosis. There exists heterogeneity in TKI response among different hematopoietic populations in CML. The abundances of these TKI-sensitive and TKI-insensitive populations differ from patient to patient and contribute to response heterogeneity. It is becoming clear that targeting the BCR-ABL1 kinase through TKIs is only one part of the equation, and TKI usage alone may not cure the majority of patients with CML. Considerable effort should be devoted to targeting the BCR-ABL1-independent mechanisms of resistance and persistence of CML LSCs.
Collapse
|
3
|
Randomized study of imatinib for chronic myeloid leukemia: comparing standard dose escalation with aggressive escalation. Blood Adv 2020; 3:312-319. [PMID: 30705033 DOI: 10.1182/bloodadvances.2018025981] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2018] [Accepted: 12/29/2018] [Indexed: 01/12/2023] Open
Abstract
In 2007, we conducted a prospective randomized study to compare an aggressive dose escalation (group B, n = 123) with the standard dose escalation proposed by European LeukemiaNet (group A, n = 122). In group B, if patients did not achieve a complete cytogenetic response (CCyR) at 3 months or did not achieve a major molecular response (MR3) at 6 months, imatinib was increased to 600 mg. At 6 months CCyR was achieved in 69.4% and 78.7% of patients in groups A and B, respectively. The rate of MR3 at 12 months and 24 months were similar in group A (52.1% and 70.0%) and group B (58.7% and 68.3%). The cumulative incidence of withdrawal by failure without accelerated/blast phase was higher in group A than in group B (9.2% vs 2.5% at 24 months). At 3 and 6 months, the protocol called for the imatinib dose to increase to 600 mg in 90 patients (74.4%) in group B. Among the 42 patients who received increased dose according to the protocol, 25 (60.0%) achieved MR3 at 12 months, whereas only 14 (35.0%) of 40 patients who did not receive an increased dose achieved MR3 (P < .05). The number of patients who withdrew from this study was similar (group A, 20%; group B, 21%). The early aggressive dose escalation failed to produce a better molecular response at 12 months. However, for patients who tolerate imatinib well, but show inadequate response at an early time point, aggressive dose escalation may contribute to achieving a better outcome. This study was registered at http://www.umin.ac.jp/ctr/ as #R000000965.
Collapse
|
4
|
Koch D, Eisinger RS, Gebharter A. A causal Bayesian network model of disease progression mechanisms in chronic myeloid leukemia. J Theor Biol 2017; 433:94-105. [DOI: 10.1016/j.jtbi.2017.08.023] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2017] [Revised: 08/16/2017] [Accepted: 08/29/2017] [Indexed: 10/18/2022]
|
5
|
Woywod C, Gruber FX, Engh RA, Flå T. Dynamical models of mutated chronic myelogenous leukemia cells for a post-imatinib treatment scenario: Response to dasatinib or nilotinib therapy. PLoS One 2017; 12:e0179700. [PMID: 28678800 PMCID: PMC5497988 DOI: 10.1371/journal.pone.0179700] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2016] [Accepted: 06/02/2017] [Indexed: 01/05/2023] Open
Abstract
Targeted inhibition of the oncogenic BCR-ABL1 fusion protein using the ABL1 tyrosine kinase inhibitor imatinib has become standard therapy for chronic myelogenous leukemia (CML), with most patients reaching total and durable remission. However, a significant fraction of patients develop resistance, commonly due to mutated ABL1 kinase domains. This motivated development of second-generation drugs with broadened or altered protein kinase selectivity profiles, including dasatinib and nilotinib. Imatinib-resistant patients undergoing treatment with second-line drugs typically develop resistance to them, but dynamic and clonal properties of this response differ. Shared, however, is the observation of clonal competition, reflected in patterns of successive dominance of individual clones. We present three deterministic mathematical models to study the origins of clinically observed dynamics. Each model is a system of coupled first-order differential equations, considering populations of three mutated active stem cell strains and three associated pools of differentiated cells; two models allow for activation of quiescent stem cells. Each approach is distinguished by the way proliferation rates of the primary stem cell reservoir are modulated. Previous studies have concentrated on simulating the response of wild-type leukemic cells to imatinib administration; our focus is on modelling the time dependence of imatinib-resistant clones upon subsequent exposure to dasatinib or nilotinib. Performance of the three computational schemes to reproduce selected CML patient profiles is assessed. While some simple cases can be approximated by a basic design that does not invoke quiescence, others are more complex and require involvement of non-cycling stem cells for reproduction. We implement a new feedback mechanism for regulation of coupling between cycling and non-cycling stem cell reservoirs that depends on total cell populations. A bifurcation landscape analysis is also performed for solutions to the basic ansatz. Computational models reproducing patient data illustrate potential dynamic mechanisms that may guide optimization of therapy of drug resistant CML.
Collapse
Affiliation(s)
- Clemens Woywod
- Centre for Theoretical and Computational Chemistry, Chemistry Department, University of Tromsø - The Arctic University of Norway, N-9037 Tromsø, Norway
- * E-mail:
| | - Franz X. Gruber
- NORSTRUCT, Chemistry Department, University of Tromsø - The Arctic University of Norway, N-9037 Tromsø, Norway
| | - Richard A. Engh
- NORSTRUCT, Chemistry Department, University of Tromsø - The Arctic University of Norway, N-9037 Tromsø, Norway
| | - Tor Flå
- Centre for Theoretical and Computational Chemistry, Chemistry Department, University of Tromsø - The Arctic University of Norway, N-9037 Tromsø, Norway
- Mathematics Department, University of Tromsø - The Arctic University of Norway, N-9037 Tromsø, Norway
| |
Collapse
|
6
|
A Hierarchical Probability Model of Colon Cancer. ADV APPL PROBAB 2016. [DOI: 10.1017/s0001867800006042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
We consider a model of fixed sizeN= 2lin which there arelgenerations of daughter cells and a stem cell. In each generationithere are 2i−1daughter cells. At each integral time unit the cells split so that the stem cell splits into a stem cell and generation 1 daughter cell and the generationidaughter cells become two cells of generationi+1. The last generation is removed from the population. A stem cell acquires first and second mutations at ratesu1andu2, and a daughter cell acquires first and second mutations at ratesv1andv2. We find the distribution for the time it takes to acquire two mutations asNgoes to ∞ and the mutation rates go to 0. The mutation rates may tend to 0 at different speeds. We also find the distribution for the locations of the mutations. In particular, we determine whether or not the mutations occur on a stem cell and if not, at what generation in the daughter cells they occur. Several outcomes are possible, depending on how fast the rates go to 0. The model considered has been proposed by Komarova (2007) as a model for colon cancer.
Collapse
|
7
|
Kelly M. A Hierarchical Probability Model of Colon Cancer. ADV APPL PROBAB 2016. [DOI: 10.1239/aap/1354716589] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
We consider a model of fixed sizeN= 2lin which there arelgenerations of daughter cells and a stem cell. In each generationithere are 2i−1daughter cells. At each integral time unit the cells split so that the stem cell splits into a stem cell and generation 1 daughter cell and the generationidaughter cells become two cells of generationi+1. The last generation is removed from the population. A stem cell acquires first and second mutations at ratesu1andu2, and a daughter cell acquires first and second mutations at ratesv1andv2. We find the distribution for the time it takes to acquire two mutations asNgoes to ∞ and the mutation rates go to 0. The mutation rates may tend to 0 at different speeds. We also find the distribution for the locations of the mutations. In particular, we determine whether or not the mutations occur on a stem cell and if not, at what generation in the daughter cells they occur. Several outcomes are possible, depending on how fast the rates go to 0. The model considered has been proposed by Komarova (2007) as a model for colon cancer.
Collapse
|
8
|
Abstract
Both acute myeloid leukemia and chronic myeloid leukemia are thought to arise from a subpopulation of primitive cells, termed leukemic stem cells that share properties with somatic stem cells. Leukemic stem cells are capable of continued self-renewal, and are resistant to conventional chemotherapy and are considered to be responsible for disease relapse. In recent years, improved understanding of the underlying mechanisms of myeloid leukemia biology has led to the development of novel and targeted therapies. This review focuses on clinically relevant patent applications and their relevance within the known literature in two areas of prevailing therapeutic interest, namely monoclonal antibody therapy and small molecule inhibitors in disease-relevant signaling pathways.
Collapse
|
9
|
Radivoyevitch T, Li H, Sachs RK. Etiology and treatment of hematological neoplasms: stochastic mathematical models. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2014; 844:317-46. [PMID: 25480649 DOI: 10.1007/978-1-4939-2095-2_16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/18/2023]
Abstract
Leukemias are driven by stemlike cancer cells (SLCC), whose initiation, growth, response to treatment, and posttreatment behavior are often "stochastic", i.e., differ substantially even among very similar patients for reasons not observable with present techniques. We review the probabilistic mathematical methods used to analyze stochastics and give two specific examples. The first example concerns a treatment protocol, e.g., for acute myeloid leukemia (AML), where intermittent cytotoxic drug dosing (e.g., once each weekday) is used with intent to cure. We argue mathematically that, if independent SLCC are growing stochastically during prolonged treatment, then, other things being equal, front-loading doses are more effective for tumor eradication than back loading. We also argue that the interacting SLCC dynamics during treatment is often best modeled by considering SLCC in microenvironmental niches, with SLCC-SLCC interactions occurring only among SLCC within the same niche, and we present a stochastic dynamics formalism, involving "Poissonization," applicable in such situations. Interactions at a distance due to partial control of total cell numbers are also considered. The second half of this chapter concerns chromosomal aberrations, lesions known to cause some leukemias. A specific example is the induction of a Philadelphia chromosome by ionizing radiation, subsequent development of chronic myeloid leukemia (CML), CML treatment, and treatment outcome. This time evolution involves a coordinated sequence of > 10 steps, each stochastic in its own way, at the subatomic, molecular, macromolecular, cellular, tissue, and population scales, with corresponding time scales ranging from picoseconds to decades. We discuss models of these steps and progress in integrating models across scales.
Collapse
Affiliation(s)
- Tomas Radivoyevitch
- Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH, USA,
| | | | | |
Collapse
|
10
|
Mencalha AL, Corrêa S, Abdelhay E. Role of calcium-dependent protein kinases in chronic myeloid leukemia: combined effects of PKC and BCR-ABL signaling on cellular alterations during leukemia development. Onco Targets Ther 2014; 7:1247-54. [PMID: 25045273 PMCID: PMC4099416 DOI: 10.2147/ott.s64303] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Calcium-dependent protein kinases (PKCs) function in a myriad of cellular processes, including cell-cycle regulation, proliferation, hematopoietic stem cell differentiation, apoptosis, and malignant transformation. PKC inhibitors, when targeted to these pathways, have demonstrated efficacy against several types of solid tumors as well as leukemia. Chronic myeloid leukemia (CML) represents 20% of all adult leukemia. The aberrant Philadelphia chromosome has been reported as the main cause of CML development in hematopoietic stem cells, due to the formation of the BCR-ABL oncogene. PKCs and BCR-ABL coordinate several signaling pathways that are crucial to cellular malignant transformation. Experimental and clinical evidence suggests that pharmacological approaches using PKC inhibitors may be effective in the treatment of CML. This mini review summarizes articles from the National Center for Biotechnology Information website that have shown evidence of the involvement of PKC in CML.
Collapse
Affiliation(s)
- André L Mencalha
- Biophysics and Biometry Department, Roberto Alcântara Gomes Biology Institute, Rio de Janeiro's State University (UERJ), Rio de Janeiro, Brazil
| | - Stephany Corrêa
- Bone Marrow Transplantation Unit (CEMO), National Cancer Institute (INCA), Rio de Janeiro, Brazil
| | - Eliana Abdelhay
- Bone Marrow Transplantation Unit (CEMO), National Cancer Institute (INCA), Rio de Janeiro, Brazil
| |
Collapse
|
11
|
Radivoyevitch T, Hlatky L, Landaw J, Sachs RK. Quantitative modeling of chronic myeloid leukemia: insights from radiobiology. Blood 2012; 119:4363-71. [PMID: 22353999 PMCID: PMC3362357 DOI: 10.1182/blood-2011-09-381855] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2011] [Accepted: 02/13/2012] [Indexed: 11/20/2022] Open
Abstract
Mathematical models of chronic myeloid leukemia (CML) cell population dynamics are being developed to improve CML understanding and treatment. We review such models in light of relevant findings from radiobiology, emphasizing 3 points. First, the CML models almost all assert that the latency time, from CML initiation to diagnosis, is at most ∼10 years. Meanwhile, current radiobiologic estimates, based on Japanese atomic bomb survivor data, indicate a substantially higher maximum, suggesting longer-term relapses and extra resistance mutations. Second, different CML models assume different numbers, between 400 and 10(6), of normal HSCs. Radiobiologic estimates favor values>10(6) for the number of normal cells (often assumed to be the HSCs) that are at risk for a CML-initiating BCR-ABL translocation. Moreover, there is some evidence for an HSC dead-band hypothesis, consistent with HSC numbers being very different across different healthy adults. Third, radiobiologists have found that sporadic (background, age-driven) chromosome translocation incidence increases with age during adulthood. BCR-ABL translocation incidence increasing with age would provide a hitherto underanalyzed contribution to observed background adult-onset CML incidence acceleration with age, and would cast some doubt on stage-number inferences from multistage carcinogenesis models in general.
Collapse
MESH Headings
- Adult
- Humans
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/epidemiology
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/etiology
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy
- Models, Biological
- Models, Theoretical
- Nuclear Weapons
- Radiation, Ionizing
- Radiobiology/methods
- Recurrence
- Survivors/statistics & numerical data
- Time Factors
Collapse
Affiliation(s)
- Tomas Radivoyevitch
- Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH, USA
| | | | | | | |
Collapse
|
12
|
Chomel JC, Turhan AG. Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy. Oncotarget 2012; 2:713-27. [PMID: 21946665 PMCID: PMC3248215 DOI: 10.18632/oncotarget.333] [Citation(s) in RCA: 61] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023] Open
Abstract
Targeted therapies of chronic myeloid leukemia (CML) using tyrosine kinase inhibitors (TKI) have profoundly changed the natural history of the disease with a major impact on survival. Molecular monitoring with BCR-ABL quantification shows that a status of undetectable molecular residual disease (UMRD) is obtained in a significant minority of patients. However, it remains unclear whether these patients are definitively cured of their leukemia. Imatinib mesylate withdrawal trials have demonstrated the rapid appearance of the malignant clone in the majority of the patients whereas some patients remain in a state of UMRD. It has clearly been demonstrated that the most primitive stem cells are refractory to all TKIs used in clinical practice. In addition, long-term dormancy is one of the most fundamental characteristics of hematopoietic stem cells. In this context, we have recently undertaken a systematic analysis of the bone marrow stem cell compartment in several patients in durable UMRD. We have demonstrated the long-term persistence of a considerable amount of BCR-ABL-expressing stem cells, even in the absence of relapse. The phenomenon of long-term leukemic stem cell dormancy is of major importance in CML and one of the key questions in cancer biology in general. We discuss, here, the potential mechanisms, including intrinsic and microenvironmental factors, that control the response of leukemic stem cells (LSCs) to targeted therapies and potential novel strategies currently in progress with a curative intent. Moreover, we propose a molecular evaluation of the residual LSC compartment in selected patients in order to develop rational TKI-cessation strategies in CML.
Collapse
Affiliation(s)
- Jean-Claude Chomel
- Service d'Hématologie et Oncologie Biologique, CHU de Poitiers, Université de Poitiers, France
| | | |
Collapse
|
13
|
Caulin AF, Maley CC. Peto's Paradox: evolution's prescription for cancer prevention. Trends Ecol Evol 2011; 26:175-82. [PMID: 21296451 DOI: 10.1016/j.tree.2011.01.002] [Citation(s) in RCA: 219] [Impact Index Per Article: 16.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2010] [Revised: 01/08/2011] [Accepted: 01/10/2011] [Indexed: 02/08/2023]
Abstract
The evolution of multicellularity required the suppression of cancer. If every cell has some chance of becoming cancerous, large, long-lived organisms should have an increased risk of developing cancer compared with small, short-lived organisms. The lack of correlation between body size and cancer risk is known as Peto's paradox. Animals with 1000 times more cells than humans do not exhibit an increased cancer risk, suggesting that natural mechanisms can suppress cancer 1000 times more effectively than is done in human cells. Because cancer has proven difficult to cure, attention has turned to cancer prevention. In this review, similar to pharmaceutical companies mining natural products, we seek to understand how evolution has suppressed cancer to develop ultimately improved cancer prevention in humans.
Collapse
Affiliation(s)
- Aleah F Caulin
- Genomics and Computational Biology Graduate Group, University of Pennsylvania, Philadelphia, PA, USA.
| | | |
Collapse
|
14
|
Sachs RK, Johnsson K, Hahnfeldt P, Luo J, Chen A, Hlatky L. A multicellular basis for the origination of blast crisis in chronic myeloid leukemia. Cancer Res 2011; 71:2838-47. [PMID: 21487044 DOI: 10.1158/0008-5472.can-10-4600] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Chronic myeloid leukemia (CML) is characterized by a specific chromosome translocation, and its pathobiology is considered comparatively well understood. Thus, quantitative analysis of CML and its progression to blast crisis may help elucidate general mechanisms of carcinogenesis and cancer progression. Hitherto, it has been widely postulated that CML blast crisis originates mainly via cell-autonomous mechanisms such as secondary mutations or genomic instability. However, recent results suggest that carcinogenic transformation may be an inherently multicellular event, in departure from the classic unicellular paradigm. We investigate this possibility in the case of blast crisis origination in CML. A quantitative, mechanistic cell population dynamics model was employed. This model used recent data on imatinib-treated CML; it also used earlier clinical data, not previously incorporated into current mathematical CML/imatinib models. With the pre-imatinib data, which include results on many more blast crises, we obtained evidence that the driving mechanism for blast crisis origination is a cooperation between specific cell types. Assuming leukemic-normal interactions resulted in a statistically significant improvement over assuming either cell-autonomous mechanisms or interactions between leukemic cells. This conclusion was robust with regard to changes in the model's adjustable parameters. Application of the results to patients treated with imatinib suggests that imatinib may act not only on malignant blast precursors, but also, to a limited degree, on the malignant blasts themselves.
Collapse
Affiliation(s)
- Rainer K Sachs
- Department of Mathematics, University of California, Berkeley, California 94720, USA.
| | | | | | | | | | | |
Collapse
|
15
|
Pizzolato N, Persano Adorno D, Valenti D, Spagnolo B. Stochastic dynamics of leukemic cells under an intermittent targeted therapy. Theory Biosci 2011; 130:203-10. [PMID: 21479663 DOI: 10.1007/s12064-011-0127-y] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2009] [Accepted: 02/14/2011] [Indexed: 11/30/2022]
Abstract
The evolutionary dynamics of cancerous cell populations in a model of Chronic Myeloid Leukemia (CML) is investigated in the presence of an intermittent targeted therapy. Cancer development and progression is modeled by simulating the stochastic evolution of initially healthy cells which can experience genetic mutations and modify their reproductive behavior, becoming leukemic clones. Front line therapy for the treatment of patients affected by CML is based on the administration of tyrosine kinase inhibitors, namely imatinib (Gleevec) or, more recently, dasatinib or nilotinib. Despite the fact that they represent the first example of a successful molecular targeted therapy, the development of resistance to these drugs is observed in a proportion of patients, especially those in advanced stages. In this study, we simulate an imatinib-like treatment of CML by modifying the fitness and the death rate of cancerous cells and describe the several scenarios in the evolutionary dynamics of white blood cells as a consequence of the efficacy of the different modeled therapies. The patient response to the therapy is investigated by simulating a drug administration following a continuous or pulsed time scheduling. A permanent disappearance of leukemic clones is achieved with a continuous therapy. This theoretical behavior is in a good agreement with that observed in previous clinical investigations. However, these findings demonstrate that an intermittent therapy could represent a valid alternative in patients with high risk of toxicity. A suitable tuned pulsed therapy can also reduce the probability of developing resistance.
Collapse
Affiliation(s)
- Nicola Pizzolato
- Dipartimento di Fisica, Group of Interdisciplinary Physics, Università di Palermo, Viale delle Scienze, ed. 18, 90128, Palermo, Italy.
| | | | | | | |
Collapse
|
16
|
PDGFRA rearrangement leading to hyper-eosinophilia, T-lymphoblastic lymphoma, myeloproliferative neoplasm and precursor B-cell acute lymphoblastic leukemia. Leukemia 2010; 25:371-5. [PMID: 21304535 DOI: 10.1038/leu.2010.272] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
17
|
Kobayashi S, Sato K, Kobayashi A, Osawa Y, Nakamura Y, Kimura F. Imatinib-resistant lymphoid clone of chronic myelogenous leukemia in blast phase arising from B cell-committed progenitor leukemic stem cells. Ann Hematol 2010; 90:367-8. [PMID: 20556391 DOI: 10.1007/s00277-010-1008-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2010] [Accepted: 06/06/2010] [Indexed: 11/26/2022]
MESH Headings
- Adult
- Antineoplastic Agents/pharmacology
- Antineoplastic Agents/therapeutic use
- B-Lymphocytes/pathology
- Benzamides
- Blast Crisis
- Clone Cells
- Drug Resistance, Neoplasm
- Humans
- Imatinib Mesylate
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology
- Male
- Mutation
- Neoplastic Stem Cells/pathology
- Piperazines/pharmacology
- Piperazines/therapeutic use
- Precursor Cells, B-Lymphoid/pathology
- Pyrimidines/pharmacology
- Pyrimidines/therapeutic use
Collapse
|
18
|
Enderling H, Anderson AR, Chaplain MA, Beheshti A, Hlatky L, Hahnfeldt P. Paradoxical Dependencies of Tumor Dormancy and Progression on Basic Cell Kinetics. Cancer Res 2009; 69:8814-21. [DOI: 10.1158/0008-5472.can-09-2115] [Citation(s) in RCA: 136] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
19
|
Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib. PLoS Comput Biol 2009; 5:e1000503. [PMID: 19749982 PMCID: PMC2730033 DOI: 10.1371/journal.pcbi.1000503] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2009] [Accepted: 08/11/2009] [Indexed: 11/19/2022] Open
Abstract
Imatinib mesylate induces complete cytogenetic responses in patients with chronic myeloid leukemia (CML), yet many patients have detectable BCR-ABL transcripts in peripheral blood even after prolonged therapy. Bone marrow studies have shown that this residual disease resides within the stem cell compartment. Quiescence of leukemic stem cells has been suggested as a mechanism conferring insensitivity to imatinib, and exposure to the Granulocyte-Colony Stimulating Factor (G-CSF), together with imatinib, has led to a significant reduction in leukemic stem cells in vitro. In this paper, we design a novel mathematical model of stem cell quiescence to investigate the treatment response to imatinib and G-CSF. We find that the addition of G-CSF to an imatinib treatment protocol leads to observable effects only if the majority of leukemic stem cells are quiescent; otherwise it does not modulate the leukemic cell burden. The latter scenario is in agreement with clinical findings in a pilot study administering imatinib continuously or intermittently, with or without G-CSF (GIMI trial). Furthermore, our model predicts that the addition of G-CSF leads to a higher risk of resistance since it increases the production of cycling leukemic stem cells. Although the pilot study did not include enough patients to draw any conclusion with statistical significance, there were more cases of progression in the experimental arms as compared to continuous imatinib. Our results suggest that the additional use of G-CSF may be detrimental to patients in the clinic. Imatinib mesylate (Gleevec) is currently the standard treatment for chronic myeloid leukemia (CML) and elicits a large reduction in leukemic cell burden in most patients. However, strong evidence suggests that imatinib does not cure the disease; approximately 20% of patients relapse within three years, and discontinuation of imatinib therapy often leads to a rebound of the leukemic cell burden. Laboratory studies have suggested that there exists a subpopulation of “quiescent” leukemia cells (i.e., cells that do not divide) that may be insensitive to imatinib treatment. It has been postulated that the disease outcome may be improved by administering imatinib in conjunction with the Granulocyte-Colony Stimulating Factor (G-CSF), a growth factor which “wakes up” the quiescent stem cells and sensitizes them to imatinib. In this study, we design a novel mathematical model of stem cell quiescence to investigate the treatment response to imatinib and G-CSF. We find that adding G-CSF to an imatinib treatment protocol leads to observable effects only if the majority of leukemic stem cells are quiescent. Our model also predicts that adding G-CSF leads to a higher risk of resistance, since it increases the number of leukemic stem cell divisions and thus the probability of acquiring a resistance mutation.
Collapse
|
20
|
Yong AS, Melo JV. The impact of gene profiling in chronic myeloid leukaemia. Best Pract Res Clin Haematol 2009; 22:181-90. [DOI: 10.1016/j.beha.2009.04.002] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|
21
|
Cancer stem cell-directed therapies: recent data from the laboratory and clinic. Mol Ther 2008; 17:219-30. [PMID: 19066601 DOI: 10.1038/mt.2008.254] [Citation(s) in RCA: 135] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
Cancer stem cells (CSCs) are defined by their ability to (i) fully recapitulate the tumor of origin when transplanted into immunodeficient mouse hosts, and (ii) self-renew, demonstrated by their ability to be serially transplanted. These properties suggest that CSCs are required for tumor maintenance and metastasis; thus, it has been predicted that CSC elimination is required for cure. This prediction has profoundly altered paradigms for cancer research, compelling investigators to prospectively isolate CSCs to characterize the molecular pathways regulating their behavior. Many potential strategies for CSC-directed therapy have been proposed, but few studies have rigorously demonstrated their efficacy using in vivo models. Herein, we highlight recent studies that demonstrate the utility of CSC-directed therapies and discuss the implications of the CSC hypothesis to experimental design and therapeutic strategies.
Collapse
|
22
|
Abstract
Human cancers are thought to be sustained in their growth by a pathologic counterpart of normal adult stem cells: cancer stem cells. This concept was first developed in human myeloid leukemias and is today being extended to solid tumors such as breast and brain cancers. A quantitative understanding of cancer stem cells requires a mathematical framework to describe the dynamics of cancer initiation and progression, the response to treatment, and the evolution of resistance. In this review, I use chronic myeloid leukemia as an example to discuss how mathematical and computational techniques have been used to gain insights into the biology of cancer stem cells.
Collapse
Affiliation(s)
- Franziska Michor
- Computational Biology Center, Memorial Sloan Kettering Cancer Center, 417 East 68th St, New York, NY 10065, USA.
| |
Collapse
|
23
|
Morinaga K, Yamauchi T, Kimura S, Maekawa T, Ueda T. Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants withBCR-ABLgene amplification. Int J Cancer 2008; 122:2621-7. [DOI: 10.1002/ijc.23435] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
24
|
Abstract
How a cancer is initiated and established remains elusive despite all the advances in decades of cancer research. Recently the cancer stem cell (CSC) hypothesis has been revived, challenging the long-standing model of "clonal evolution" for cancer development and implicating the dawning of a potential cure for cancer [1]. The recent identification of precancerous stem cells (pCSCs) in cancer, an early stage of CSC development, however, implicates that the "clonal evolution" is not contradictory to the CSC hypothesis, but is rather an aspect of the process of CSC development [2]. The discovery of pCSC has revealed and will continue to reveal the volatile properties of CSC with respects to their phenotype, differentiation and tumorigenic capacity during initiation and progression. Both pCSC and CSC might also serve as precursors of tumor stromal components such as tumor vasculogenic stem/progenitor cells (TVPCs). Thus, the CSC hypothesis covers the developing process of tumor-initiating cells (TIC) --> pCSC --> CSC --> cancer, a cellular process that should parallel the histological process of hyperplasia/metaplasia (TIC) --> precancerous lesions (pCSC) --> malignant lesions (CSC --> cancer). The embryonic stem (ES) cell and germline stem (GS) cell genes are subverted in pCSCs. Especially the GS cell protein piwil2 may play an important role during the development of TIC --> pCSC --> CSC, and this protein may be used as a common biomarker for early detection, prevention, and treatment of cancer. As cancer stem cell research is yet in its infancy, definitive conclusions regarding the role of pCSC can not be made at this time. However this review will discuss what we have learned from pCSC and how this has led to innovative ideas that may eventually have major impacts on the understanding and treatment of cancer.
Collapse
Affiliation(s)
- Jian-Xin Gao
- Department of Pathology and Comprehensive Cancer Center, Medical Center, Ohio State University, Columbus, OH 43210, USA.
| |
Collapse
|
25
|
Fontana S, Alessandro R, Barranca M, Giordano M, Corrado C, Zanella-Cleon I, Becchi M, Kohn EC, De Leo G. Comparative Proteome Profiling and Functional Analysis of Chronic Myelogenous Leukemia Cell Lines. J Proteome Res 2007; 6:4330-42. [DOI: 10.1021/pr0704128] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
26
|
Abstract
Chronic myeloid leukaemia (CML) can be considered as a paradigm for neoplasias that evolve through a multi-step process. CML is also one of the best examples of a disease that can be targeted by molecular therapy; however, the success of new 'designer drugs' is largely restricted to the chronic phase of the disease. If not cured at this stage, CML invariably progresses and transforms into an acute-type leukaemia undergoing a 'blast crisis'. The causes of this transformation are still poorly understood. What mechanisms underlie this progression, and are they shared by other common cancers?
Collapse
Affiliation(s)
- Junia V Melo
- Department of Haematology, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK.
| | | |
Collapse
|